Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

BACKGROUND: Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg). In this study, we investigated whether inhibiting Treg activity with ipilimumab duri...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yano, Hiroshi, Thakur, Archana, Tomaszewski, Elyse N, Choi, Minsig, Deol, Abhinav, Lum, Lawrence G
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2014
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4105782/
https://ncbi.nlm.nih.gov/pubmed/25008236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-12-191
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak